Therefore, a more targeted analysis of the peripheral effects of CSF1R inhibition in ongoing or planned clinical trials is necessary, to better ponder the long-term side effects of potential therapies for Alzheimer’s disease. The gene discussed is CSF1R; the disease is early-onset autosomal dominant Alzheimer disease.